Please login to the form below

Not currently logged in
Email:
Password:

R&D news in brief

Our weekly round-up of the R&D news in brief

Wellcome Trust set to issue bond
Medical research charity, the Wellcome Trust, will become the first charity in the UK to issue a bond this summer.

The bond issuance will allow the trust, which has an endowment of more than ?12.3bn, to raise up to £500m from the capital markets.

ìThis is bringing business expertise into the charitable sector and could encourage other endowments to do the same,î said Hugo Foxwood, analyst at credit ratings agency, Standard & Poor's, which assigned top triple-A status to the Wellcome Trust.

Trial go-ahead for Phosphagenics
Australian biotech firm, Phosphagenics, has received approval for a phase I clinical trial of transdermal insulin delivery product, TPM-02/Insulin.

TPM-02/Insulin is being developed as a novel way of administering insulin to diabetics, and the trial is now set to begin in July.

In the proposed study, 20 healthy male volunteers will be randomly assigned to receive either TPM-02/Insulin or a placebo, applied in a single dose directly to the skin.

Phosphagenics said the primary objective will be to assess the safety and tolerability of the delivery platform. Blood glucose and insulin levels will also be measured.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics